Recent 8-K filings for ALT

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 13, 2026 11:34 UTC earnings item 2.02item 9.01

  Altimmune Q1 net loss $22.6M; cash $535M; PERFORMA Phase 3 MASH trial initiation in H2 2026

source · ALT on sec.gov